---
title: PreComb
date: 2021-04-26T08:03:03Z
modified: 2026-08-12T07:11:43Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/precomb/"
type: portfolio
status: publish
excerpt: ""
wpid: 87084
language:
  - English
post_translations:
  - pll_607eed8964a57
branchen22:
  - R&D Tools
sectors:
  - Diagnostics & R&D Tools
focus_areas:
  - R&D Tools
timestamp: 2026-08-12T07:11:43Z
tags:
  - English
  - pll_607eed8964a57
  - R&D Tools
  - Diagnostics & R&D Tools
---

## Beschreibungstext

PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring precision medicine benefits to all cancer patients. PreComb is pioneering breakthrough technologies to directly test the drug response of individual cancer patients, based on patient-derived 3D microtumors. For the first time, a fully automated point-of-care solution for determining drug sensitivity or resistance directly in the clinic is being developed. This offers the unique ability to routinely test entire portfolios of cancer drugs and drug combinations in large-scale, making the technology a universal tool from drug discovery to guiding therapies.

## Unternehmenswebsite

www.precomb.com

## Adresse

PreComb Therapeutics AG
Garstligweg 8
CH-8634 Hombrechtikon
Switzerland

## Kontakt

Array